# The TELO-SCOPE Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary Fibrosis

> **NCT04638517** · PHASE2 · TERMINATED · sponsor: **The University of Queensland** · enrollment: 29 (actual)

## Conditions studied

- Pulmonary Fibrosis
- Telomere Shortening
- Telomere Disease
- Dyskeratosis Congenita

## Interventions

- **DRUG:** Danazol
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04638517
- **Lead sponsor:** The University of Queensland
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-09-07
- **Primary completion:** 2025-01-16
- **Final completion:** 2025-01-16
- **Target enrollment:** 29 (ACTUAL)
- **Why stopped:** Data Safety Monitoring Board recommended cessation due to futility
- **Last updated:** 2025-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04638517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04638517, "The TELO-SCOPE Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary Fibrosis". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT04638517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*